HB Wealth Management LLC Buys New Stake in SAB Biotherapeutics, Inc. $SABS

HB Wealth Management LLC purchased a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 307,500 shares of the company’s stock, valued at approximately $618,000. HB Wealth Management LLC owned about 2.95% of SAB Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SABS. UBS Group began coverage on SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $7.00 target price on the stock. Leerink Partners started coverage on SAB Biotherapeutics in a research report on Wednesday, September 17th. They issued an “outperform” rating and a $7.00 price objective on the stock. Chardan Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of SAB Biotherapeutics in a report on Thursday, December 18th. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Finally, Leerink Partnrs upgraded shares of SAB Biotherapeutics to a “strong-buy” rating in a research report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS opened at $3.94 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.50 and a current ratio of 10.49. The stock has a market capitalization of $187.58 million, a PE ratio of -1.28 and a beta of 0.58. SAB Biotherapeutics, Inc. has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The company has a fifty day moving average of $3.72 and a two-hundred day moving average of $2.84.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.38. As a group, research analysts forecast that SAB Biotherapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

SAB Biotherapeutics Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.